T. Rowe Price Investment Management Inc. Sells 212,289 Shares of Teleflex Incorporated $TFX

T. Rowe Price Investment Management Inc. lowered its position in shares of Teleflex Incorporated (NYSE:TFX) by 4.6% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 4,356,754 shares of the medical technology company’s stock after selling 212,289 shares during the quarter. T. Rowe Price Investment Management Inc. owned 0.10% of Teleflex worth $531,699,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Invesco Ltd. increased its position in shares of Teleflex by 3.0% in the fourth quarter. Invesco Ltd. now owns 162,882 shares of the medical technology company’s stock valued at $19,878,000 after acquiring an additional 4,807 shares during the period. Alberta Investment Management Corp bought a new position in shares of Teleflex during the fourth quarter valued at about $1,318,000. Vident Advisory LLC boosted its holdings in shares of Teleflex by 2.8% during the fourth quarter. Vident Advisory LLC now owns 6,992 shares of the medical technology company’s stock worth $853,000 after purchasing an additional 188 shares during the period. State of Tennessee Department of Treasury boosted its holdings in shares of Teleflex by 4.7% during the fourth quarter. State of Tennessee Department of Treasury now owns 22,374 shares of the medical technology company’s stock worth $2,731,000 after purchasing an additional 998 shares during the period. Finally, Fuller & Thaler Asset Management Inc. grew its stake in shares of Teleflex by 21.3% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 696,950 shares of the medical technology company’s stock worth $85,056,000 after purchasing an additional 122,481 shares during the last quarter. Institutional investors own 95.62% of the company’s stock.

Teleflex Stock Performance

Shares of TFX opened at $126.97 on Friday. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.55 and a quick ratio of 2.03. Teleflex Incorporated has a one year low of $100.18 and a one year high of $139.67. The company has a 50-day simple moving average of $129.54 and a two-hundred day simple moving average of $119.33. The firm has a market capitalization of $5.62 billion, a PE ratio of -5.57, a price-to-earnings-growth ratio of 0.93 and a beta of 0.82.

Teleflex (NYSE:TFX) last posted its earnings results on Thursday, May 7th. The medical technology company reported $1.39 earnings per share for the quarter, topping analysts’ consensus estimates of $1.21 by $0.18. Teleflex had a positive return on equity of 13.29% and a negative net margin of 35.88%.The firm had revenue of $548.30 million for the quarter, compared to the consensus estimate of $536.91 million. During the same quarter in the prior year, the business earned $1.44 EPS. The business’s revenue for the quarter was up 32.3% on a year-over-year basis. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. On average, analysts anticipate that Teleflex Incorporated will post 6.7 EPS for the current fiscal year.

Teleflex Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Monday, May 25th will be given a dividend of $0.34 per share. The ex-dividend date is Friday, May 22nd. This represents a $1.36 annualized dividend and a dividend yield of 1.1%. Teleflex’s payout ratio is currently -5.96%.

Wall Street Analysts Forecast Growth

A number of research firms have commented on TFX. Wall Street Zen lowered Teleflex from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Piper Sandler upgraded Teleflex from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $140.00 to $160.00 in a research report on Monday, June 8th. Raymond James Financial reissued an “outperform” rating and set a $150.00 target price on shares of Teleflex in a research note on Friday, May 8th. Needham & Company LLC upped their target price on Teleflex from $138.00 to $147.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Teleflex in a research note on Friday, March 27th. Four equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Teleflex currently has an average rating of “Hold” and an average price target of $146.00.

Teleflex Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.